Camurus gains PBS listing of long-acting Buvidal as opioid dependence therapy

26 August 2019

Australian Federal Health Minister Greg Hunt announced on Sunday that Swedish drugmaker Camurus’ (STO: CAMX) long-acting medication Buvidal (buprenorphine) Weekly and Monthly solutions for injection will be listed on the country’s Pharmaceutical Benefit Scheme (PBS).

From September, Buvidal will be fully subsidized as a part of a A$40 million (~$27 million) investment by the Australian government, with the news pushing Camurus’ shares up 4.7% to 82.00 Swedish kronor in trading this morning.

Over 110,000 Australians are currently struggling with opioid dependence with increasing deaths from overdose. Approximately 50,000 people receive treatments for their opioid dependence at 2,852 dosing points in Australia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK